Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex

Psychopharmacology

Volumn 224, Issue 3, 2012, Pages 363-376

  Hysek, Cédric M ^a   Liechti, Matthias E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

MDMA; Norepinephrine; Pupil; Pupillary reflex; Pupillometry; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; NORADRENALIN; SEROTONIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; MIOSIS; MYDRIASIS; NORMAL HUMAN; PARASYMPATHETIC TONE; PHOTOSTIMULATION; PRIORITY JOURNAL; PUPIL REFLEX; PUPILLOMETRY; SYMPATHETIC TONE;

ADRENERGIC AGONISTS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC UPTAKE INHIBITORS; ADULT; AFFECT; AUTONOMIC AGENTS; BODY TEMPERATURE REGULATION; CARBAZOLES; CLONIDINE; CROSS-OVER STUDIES; DOPAMINE UPTAKE INHIBITORS; DOXAZOSIN; FEMALE; HEMODYNAMICS; HUMANS; LIGHT; MALE; MIOSIS; MORPHOLINES; MYDRIASIS; MYDRIATICS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REACTION TIME; RECOVERY OF FUNCTION; REFLEX, PUPILLARY; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TIME FACTORS; YOUNG ADULT;

EID: 84871670599     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2761-6     Document Type: Article

References (57)

1. Anavekar SN, Jarrott B, Toscano M, Louis WJ (1982) Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. Eur J Clin Pharmacol 23:1-5
2. Benjamin J, Nemetz H, Fux M, Bleichman I, Agam G (1997) Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorder. J Psychiatr Res 31:489-495
3. Bitsios P, Langley RW, Szabadi E, Bradshaw CM (1996) Comparison of the effects of clonidine on tyramine- and methoxamine-evoked mydriasis in man. Br J Clin Pharmacol 41:269-275
4. Bitsios P, Szabadi E, Bradshaw CM (1999) Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man. Psychopharmacology (Berl) 143:286-292
5. Chung M, Vashi V, Puente J, Sweeney M, Meredith P (1999) Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 48:678-687
6. 2-adrenoreceptor antagonist RX 781094. Br J Clin Pharmacol 14:99-101
7. Derogatis LR, Rickels K, Rock AF (1976) The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry 128:280-289
8. Farre M, de la Torre R, Mathuna BO, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, Cami J (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173:364-375
9. Farre M, Abanades S, Roset PN, Peiro AM, Torrens M, O'Mathuna B, Segura M, de la Torre R (2007) Pharmacological interaction between 3,4- methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. J Pharmacol Exp Ther 323:954-962
10. Heller PH, Perry F, Jewett DL, Levine JD (1990) Autonomic components of the human pupillary light reflex. Invest Ophthalmol Vis Sci 31:156-162
11. Henderson LS, Tenero DM, Baidoo CA, Campanile AM, Harter AH, Boyle D, Danoff TM (2006) Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol 98:17L-26L
12. Hey JA, Gherezghiher T, Koss MC (1988) Atypical α-adrenoceptor mediates phenylephrine-induced mydriasis in anesthetized cats. J Ocul Pharmacol 4:303-310
13. Hirohashi M, Takasuna K, Tamura K, Yamaguchi K, Maekawa K, Yamada S, Iwasaki S, Yoshida M, Nomura M, Taguchi K (1990) General pharmacological profiles of the new betaadrenoceptor antagonist carvedilol. Arzneimittelforschung 40:735-746
14. Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC, Brenneisen R, Huwyler J, Liechti ME (2011) The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans. Clin Pharmacol Ther 90:246-255
15. 2-adrenergic agonist clonidine on the pharmacodynamics and pharmacokinetics of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Pharmacol Exp Ther 340:286-294
16. Hysek CM, Domes G, Liechti ME (2012b) MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions. Psychopharmacology (Berl). doi:10.1007/ s00213-012-2645-9
17. Hysek CM, Schmid Y, Rickli A, Simmler L, Donzelli M, Grouzmann E, Liechti ME (2012c) Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol. doi:10.1111/j.1476-5381.2012.01936.x
18. Hysek CM, Simmler LD, NicolaVG,Vischer N, Donzelli M, Krähenbühl S, Grouzmann E, Huwyler J, Hoener MC, Liechti ML (2012d) Duloxetine inhibits effects of MDMA ("Ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS ONE 7(5):e36476. doi:10.1371/journal.pone.0036476
19. Keranen A, Nykanen S, Taskinen J (1978) Pharmacokinetics and sideeffects of clonidine. Eur J Clin Pharmacol 13:97-101
20. Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28:432-440
21. Koss MC, Logan LG, Gherezghiher T (1988) α-Adrenoceptor activation of nictitating membrane and iris in cats. Naunyn Schmiedebergs Arch Pharmacol 337:519-524
22. Koudas V, Nikolaou A, Hourdaki E, Giakoumaki SG, Roussos P, Bitsios P (2009) Comparison of ketanserin, buspirone and propranolol on arousal, pupil size and autonomic function in healthy volunteers. Psychopharmacology (Berl) 205:1-9
23. Kramer R, Rubicek M, Turner P (1973) The role of norfenfluramine in fenfluramine-induced mydriasis. J Pharm Pharmacol 25:575-576
24. Liechti ME, Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14:269-274
25. Liechti ME, Vollenweider FX (2001) Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 16:589-598
26. Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22:513-521
27. Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154:161-168
28. Loewenfeld IE (1999) The pupil: anatomy, physiology, and clinical applications. Butterworth-Heinemann, Boston
29. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136-145
30. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome I, Doblin R (2010) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25:439-452
31. Morgan T (1994) Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 26:335-346
32. Morley MJ, Bradshaw CM, Szabadi E (1991) Effects of clonidine and yohimbine on the pupillary light reflex and carbachol-evoked sweating in healthy volunteers. Br J Clin Pharmacol 31:99-101
33. Nielsen AG, Pedersen RS, Noehr-Jensen L, Damkier P, Brosen K (2010) Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6. Eur J Clin Pharmacol 66:655-660
34. Nieuwenhuis S, van Nieuwpoort IC, Veltman DJ, Drent ML (2007) Effects of the noradrenergic agonist clonidine on temporal and spatial attention. Psychopharmacology (Berl) 193:261-269
35. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Nielsen F, Brosen K (2009) Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol 65:887-894
36. Phillips MA, Bitsios P, Szabadi E, Bradshaw CM (2000a) Comparison of the antidepressants reboxetine, fluvoxamine and amitriptyline upon spontaneous pupillary fluctuations in healthy human volunteers. Psychopharmacology (Berl) 149:72-76
37. Phillips MA, Szabadi E, Bradshaw CM (2000b) Comparison of the effects of clonidine and yohimbine on pupillary diameter at different illumination levels. Br J Clin Pharmacol 50:65-68
38. Phillips MA, Szabadi E, Bradshaw CM (2000c) Comparison of the effects of clonidine and yohimbine on spontaneous pupillary fluctuations in healthy human volunteers. Psychopharmacology (Berl) 150:85-89
39. Prow MR, Martin KF, Heal DJ (1996) 8-OH-DPAT-induced mydriasis in mice: a pharmacological characterisation. Eur J Pharmacol 317:21-28
40. Roelands B, GoekintM, Heyman E, Piacentini MF, Watson P, Hasegawa H, Buyse L, Pauwels F, De Schutter G, Meeusen R (2008) Acute norepinephrine reuptake inhibition decreases performance in normal and high ambient temperature. J Appl Physiol 105:206-212
41. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41
42. Schmitt JA, Riedel WJ, Vuurman EF, Kruizinga M, Ramaekers JG (2002) Modulation of the critical flicker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes. Psychopharmacology (Berl) 160:381-386
43. Schmitz N, Hartkamp N, Kiuse J, Franke GH, Reister G, Tress W (2000) The Symptom Check-List-90-R (SCL-90-R): a German validation study. Qual Life Res 9:185-193
44. Shirai K, Song M, Suzuki J, Kurosu T, Oyama T, Nagayama D, Miyashita Y, Yamamura S, Takahashi M (2010) Contradictory effects of beta1- and alpha1-aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI) - CAVI independent of blood pressure. J Atheroscler Thromb 18:49-55
45. Siepmann T, Ziemssen T, Mueck-Weymann M, Kirch W, Siepmann M (2007) The effects of venlafaxine on autonomic functions in healthy volunteers. J Clin Psychopharmacol 27:687-691
46. Simmler LD, Hysek CM, Liechti ME (2011) Sex differences in the effects of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin Endocrinol Metab 96:2844-2850
47. Sofuoglu M, Brown S, Babb DA, Pentel PR, Hatsukami DK (2000) Carvedilol affects the physiological and behavioral response to smoked cocaine in humans. Drug Alcohol Depend 60:69-76
48. 2-adrenoceptors. J Psychopharmacol 10(S3):S6-S18
49. Tancer M, Johanson CE (2007) The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 189:565-573
50. Taylor WR, Chen JW, Meltzer H, Gennarelli TA, Kelbch C, Knowlton S, Richardson J, Lutch MJ, Farin A, Hults KN, Marshall LF (2003) Quantitative pupillometry, a new technology: normative data and preliminary observations in patients with acute head injury: technical note. J Neurosurg 98:205-213
51. Tham TC, Guy S, McDermott BJ, Shanks RG, Riddell JG (1995) The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man. Br J Clin Pharmacol 40:19-23
52. Theofilopoulos N, McDade G, Szabadi E, Bradshaw CM (1995) Effects of reboxetine and desipramine on the kinetics of the pupillary light reflex. Br J Clin Pharmacol 39:251-255
53. Tomlinson B, Bompart F, Graham BR, Liu JB, Prichard BN (1988) Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine. Drugs 36(Suppl 6):37-47
54. Tomlinson B, Prichard BN, Graham BR, Walden RJ (1992) Clinical pharmacology of carvedilol. Clin Investig 70(Suppl 1):S27-S36
55. Verrico CD, Miller GM, Madras BK (2007) MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 189:489-503
56. White TL, Justice AJ, deWit H (2002) Differential subjective effects of D-amphetamine by gender, hormone levels and menstrual cycle phase. Pharmacol Biochem Behav 73:729-741
57. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M (1997) SKID-I: Strukturiertes Klinisches Interview für DSM-IV. Hogrefe-Verlag, Göttingen